Literature DB >> 7537574

Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivo.

T Oikawa1, C Onozawa, M Sakaguchi, I Morita, S Murota.   

Abstract

Three isoforms of platelet-derived growth factors (PDGFs) composing of AA, AB, and BB chains all exhibited angiogenic activity in a dose-dependent manner in an in vivo assay system involving the chorioallantoic membrane of chick embryo. The order of potency as BB > AB = AA. They, however, failed to stimulate proliferation of vascular endothelial cells, suggesting that their effects are indirect. These data suggest that possibility that three PDGF isoforms are indirect angiogenic factors.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7537574     DOI： 10.1248/bpb.17.1686

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN： 0918-6158            Impact factor:   2.233


  11 in total

1.  The effect of Emdogain and platelet-derived growth factor on the osteoinductive potential of hydroxyapatite tricalcium phosphate.

Authors:  R C Chan; V Marino; P M Bartold
Journal:  Clin Oral Investig       Date:  2011-10-28       Impact factor: 3.573

2.  Platelet-derived growth factor B-chain of hematopoietic origin is not necessary for granulation tissue formation and its absence enhances vascularization.

Authors:  B S Buetow; J R Crosby; W E Kaminski; R K Ramachandran; P Lindahl; P Martin; C Betsholtz; R A Seifert; E W Raines; D F Bowen-Pope
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

3.  Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors.

Authors:  Xuri Li; Marc Tjwa; Lieve Moons; Pierre Fons; Agnes Noel; Annelii Ny; Jian Min Zhou; Johan Lennartsson; Hong Li; Aernout Luttun; Annica Pontén; Laetitia Devy; Ann Bouché; Hideyasu Oh; Ann Manderveld; Silvia Blacher; David Communi; Pierre Savi; Françoise Bono; Mieke Dewerchin; Jean-Michel Foidart; Monica Autiero; Jean-Marc Herbert; D Collen; Carl-Henrik Heldin; Ulf Eriksson; Peter Carmeliet
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

Review 4.  Angiogenesis inhibitors: current strategies and future prospects.

Authors:  Kristina M Cook; William D Figg
Journal:  CA Cancer J Clin       Date:  2010-06-16       Impact factor: 508.702

Review 5.  Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

Authors:  Hyun-Jin Choi; Guillermo N Armaiz Pena; Sunila Pradeep; Min Soon Cho; Robert L Coleman; Anil K Sood
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

Review 6.  Targeting Angiogenic Factors for the Treatment of Medulloblastoma.

Authors:  Zahraa Saker; Mahdi Rizk; Hisham F Bahmad; Sanaa M Nabha
Journal:  Curr Treat Options Oncol       Date:  2022-04-12

7.  Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC.

Authors:  Marc S Ballas; Abraham Chachoua
Journal:  Onco Targets Ther       Date:  2011-05-30       Impact factor: 4.147

Review 8.  Angiogenesis-related pathways in the pathogenesis of ovarian cancer.

Authors:  Nikos G Gavalas; Michalis Liontos; Sofia-Paraskevi Trachana; Tina Bagratuni; Calliope Arapinis; Christine Liacos; Meletios A Dimopoulos; Aristotle Bamias
Journal:  Int J Mol Sci       Date:  2013-07-30       Impact factor: 5.923

Review 9.  Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy.

Authors:  Marius Raica; Anca Maria Cimpean
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-11

10.  A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment.

Authors:  Jessica K R Boult; Jennifer Terkelsen; Simon Walker-Samuel; Daniel P Bradley; Simon P Robinson
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.